Fragile X Syndrome Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014

Share Article

RnRMarketResearch.com adds Fragile X Syndrome Pipeline Review H2 2014 to its store. The report contain 85 pages & provides an overview of the Fragile X Syndrome therapeutic pipeline.

Fragile X Syndrome Therapeutic Pipeline Market

Fragile X Syndrome Therapeutic Pipeline Market

The report "Fragile X Syndrome Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Fragile X Syndrome is the most common inherited form of mental problems and this disease caused by changes in a single X. Complete Report is Available @ http://www.rnrmarketresearch.com/fragile-x-syndrome-pipeline-review-h2-2014-market-report.html .

Companies discussed in this Fragile X Syndrome Pipeline Review H2 2014 report include Alcobra Ltd, Confluence Pharmaceuticals LLC, Cortex Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Hua Medicine Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L., Neuren Pharmaceuticals Limited, Nexgenix Pharmaceuticals, LLC, Paratek Pharmaceuticals, Inc., Selvita SA.

Drugs profile discussed in this Fragile X Syndrome Pipeline Review H2 2014 report include acamprosate calcium, basimglurant, CX-929, Drugs to Inhibit mGluR5 for Fragile X Syndrome, ganaxolone, Metadoxine ER, minocycline, NNZ-2566, NNZ-2591, PTKMS-01, SEL-203, Small Molecule for FXTAS, Small Molecule to Activate Epsilon PKC for Fragile X Syndrome, Small Molecules to Agonize 5-HT7 for Fragile X Syndrome, Small molecules to Antagonize mGLUR5 for Fragile X Syndrome, Small Molecules to Inhibit Pak for Genetic Disorders, Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome and SRT-278. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248279 .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Major points in Table of Content
List of Tables
Number of Products under Development for Fragile X Syndrome, H2 2014
Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Comparative Analysis by Unknown Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Fragile X Syndrome - Pipeline by Alcobra Ltd, H2 2014
Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2014
Fragile X Syndrome - Pipeline by Cortex Pharmaceuticals, Inc., H2 2014
Fragile X Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014
Fragile X Syndrome - Pipeline by Hua Medicine Ltd., H2 2014
Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals, Inc., H2 2014
Fragile X Syndrome - Pipeline by MI.TO. Technology S.r.L., H2 2014
Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Limited, H2 2014
Fragile X Syndrome - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2014
Fragile X Syndrome - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014
Fragile X Syndrome - Pipeline by Selvita SA, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Fragile X Syndrome Therapeutics - Recent Pipeline Updates, H2 2014
Fragile X Syndrome - Dormant Projects, H2 2014
Fragile X Syndrome - Discontinued Products, H2 2014

Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=248279 . (This is a premium report priced at US$2000 for a single user License.)

List of Figures
Number of Products under Development for Fragile X Syndrome, H2 2014
Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

Explore more reports on Neurology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website